Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2.

In the present study, the effects of a large series of flavonoids on multidrug resistance proteins (MRPs) were studied in MRP1 and MRP2 transfected MDCKII cells. The results were used to define the structural requirements of flavonoids necessary for potent inhibition of MRP1- and MRP2-mediated calcein transport in a cellular model. Several of the methoxylated flavonoids are among the best MRP1 inhibitors (IC(50) values, ranging between 2.7 and 14.3 microM) followed by robinetin, myricetin and quercetin (IC(50) values ranging between 13.6 and 21.8 microM). Regarding inhibition of MRP2 activity especially robinetin and myricetin appeared to be good inhibitors (IC(50) values of 15.0 and 22.2 microM, respectively). Kinetic characterization revealed that the two transporters differ marginally in the apparent K(m) for the substrate calcein. For one flavonoid, robinetin, the kinetics of inhibition were studied in more detail and revealed competitive inhibition with respect to calcein, with apparent inhibition constants of 5.0 microM for MRP1 and 8.5 microM for MRP2. For inhibition of MRP1, a quantitative structure activity relationship (QSAR) was obtained that indicates three structural characteristics to be of major importance for MRP1 inhibition by flavonoids: the total number of methoxylated moieties, the total number of hydroxyl groups and the dihedral angle between the B- and C-ring. Regarding MRP2 mediated calcein efflux inhibition, only the presence of a flavonol B-ring pyrogallol group seems to be an important structural characteristic. Overall, this study provides insight in the structural characteristics involved in MRP inhibition and explores the differences between inhibitors of these two transporters, MRP1 and MRP2. Ultimately, MRP2 displays higher selectivity for flavonoid type inhibition than MRP1.

[1]  A. di Pietro,et al.  Recent advances in the discovery of flavonoids and analogs with high‐affinity binding to P‐glycoprotein responsible for cancer cell multidrug resistance , 2002, Medicinal research reviews.

[2]  H. Daniel,et al.  Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines , 1999, European journal of nutrition.

[3]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[4]  S. Cole,et al.  Glutathione Stimulates Sulfated Estrogen Transport by Multidrug Resistance Protein 1* , 2001, The Journal of Biological Chemistry.

[5]  P. van Bladeren,et al.  Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. , 2003, Chemical research in toxicology.

[6]  A. Sparreboom,et al.  Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  B. Norman Inhibitors of MRP1-mediated multidrug resistance , 1998 .

[8]  Liesbeth Geraets,et al.  Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. , 2004, Biochemical pharmacology.

[9]  S. Hladky,et al.  Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1. , 2001, Biochemical pharmacology.

[10]  P. Hollman,et al.  Absorption and disposition kinetics of the dietary antioxidant quercetin in man. , 1996, Free radical biology & medicine.

[11]  A. di Pietro,et al.  Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Molnár,et al.  Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. , 2003, Oncology research.

[13]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[14]  Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1). , 2002, Bioorganic & medicinal chemistry letters.

[15]  T. Uchiumi,et al.  Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.

[16]  S. Cole,et al.  Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. , 2001, Molecular pharmacology.

[17]  D. Keppler,et al.  ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. , 1998, Chemico-biological interactions.

[18]  A. Goffeau,et al.  Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters , 2002, Cellular and Molecular Life Sciences CMLS.

[19]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[20]  G. Szakács,et al.  Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRP1. , 1998, Anticancer research.

[21]  T. Walle,et al.  Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. , 1999, Biochemical pharmacology.

[22]  M. Essodaigui,et al.  Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. , 1998, Biochemistry.

[23]  D. Keppler,et al.  Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. , 1999, Molecular pharmacology.

[24]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[25]  P. Borst,et al.  ABC transporters in lipid transport. , 2000, Biochimica et biophysica acta.

[26]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[27]  M. Veit,et al.  Pharmacokinetics and bioavailability of the flavonol quercetin in humans. , 1999, International journal of clinical pharmacology and therapeutics.

[28]  Henryk Szymusiak,et al.  Prooxidant toxicity of polyphenolic antioxidants to HL‐60 cells: description of quantitative structure‐activity relationships , 1999, FEBS letters.

[29]  J. Lankelma,et al.  Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein , 1997, FEBS letters.

[30]  R. Evers,et al.  Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1 , 1997, FEBS letters.

[31]  D. Keppler,et al.  Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAJ) gene in liver , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[33]  R. Walgren,et al.  Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. , 2000, The Journal of pharmacology and experimental therapeutics.

[34]  K. Tomisawa,et al.  Inhibition of gastric H+, K(+)-ATPase by flavonoids: a structure-activity study. , 1999, Journal of enzyme inhibition.

[35]  M. Morris,et al.  Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. , 2003, Journal of Pharmacy and Science.

[36]  S. Cole,et al.  Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. , 1998, Cancer research.

[37]  P. Jansen,et al.  The (patho)physiological functions of the MRP family. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[38]  P. Jansen,et al.  ATP‐ and glutathione‐dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1 , 1999, British journal of pharmacology.

[39]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.